ÂÜÀòÂÒÂ×

Muna Bhanji brings more than 30 years of strategic and operational experience in the biopharmaceutical industry to Intellia's board, including a

proven track record of driving growth across a broad portfolio of medicines and vaccines. She built her career at Merck, where she held several senior

leadership roles within U.S. based sales, marketing, managed markets and commercial operations, global franchise business units, and global market

access and policy. She is the founder and president of Tiba Global Access, a commercialization and market access strategy consultancy serving the

biopharmaceutical industry.

In addition to Intellia's board, Muna serves on the board of directors for several companies, including Cytokinetics (NASDAQ: CYTK), Ardelyx, Inc. (NASDAQ:ARDX) and Veracyte, Inc. (NASDAQ: VVCYT). She also is a member of the board of Corus International, an international hunmanitarian organization working at the intersection of poverty alleviation and healthcare. Muna earned her B.S. in Pharmacy from Rutgers school of Pharmacy and an MBA from St. Joseph's University.